Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?

The development of tumor necrosis factor alpha (TNF-) inhibitors is probably one of the most significant advancement in the management of a number of inflammatory rheumatic disorders to date. High efficacy of the treatment is associated with relatively rare and very heterogeneous adverse reactions....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eugeniusz Józef Kucharz, Anna Kotulska-Kucharz
Formato:	article
Lenguaje:	EN
Publicado:	Termedia Publishing House 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/c12f29a7f5784476be57d07b8b576008
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c12f29a7f5784476be57d07b8b576008
record_format	dspace
spelling	oai:doaj.org-article:c12f29a7f5784476be57d07b8b5760082021-12-02T17:46:04ZTumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?0034-62332084-983410.5114/reum.2021.105438https://doaj.org/article/c12f29a7f5784476be57d07b8b5760082021-04-01T00:00:00Zhttps://www.termedia.pl/Tumor-necrosis-factor-alpha-inhibitors-and-demyelinating-disease-what-is-behind-it-,18,43876,1,1.htmlhttps://doaj.org/toc/0034-6233https://doaj.org/toc/2084-9834The development of tumor necrosis factor alpha (TNF-) inhibitors is probably one of the most significant advancement in the management of a number of inflammatory rheumatic disorders to date. High efficacy of the treatment is associated with relatively rare and very heterogeneous adverse reactions. The reactions are gradually recognized with an increase in number of the patients receiving medication and prolonged period of the drug usage. Neurological adverse events in patients receiving TNF- inhibitors are not common. This finding emergence a question of coincidental occurrence of the nervous system involvements as opposite to suggestion of induction of the nervous system disease or unmasking of latent disease due to the drug administration. Potential association of anti-TNF- therapy with demyelination is one of neurological adverse reaction, and is an important concern for every day clinical practice of rheumatologist as well as is an interesting problem from pathophysiological point of view.Eugeniusz Józef KucharzAnna Kotulska-KucharzTermedia Publishing HousearticleMedicineRENRheumatology, Vol 59, Iss 2, Pp 65-67 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Eugeniusz Józef Kucharz Anna Kotulska-Kucharz Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
description	The development of tumor necrosis factor alpha (TNF-) inhibitors is probably one of the most significant advancement in the management of a number of inflammatory rheumatic disorders to date. High efficacy of the treatment is associated with relatively rare and very heterogeneous adverse reactions. The reactions are gradually recognized with an increase in number of the patients receiving medication and prolonged period of the drug usage. Neurological adverse events in patients receiving TNF- inhibitors are not common. This finding emergence a question of coincidental occurrence of the nervous system involvements as opposite to suggestion of induction of the nervous system disease or unmasking of latent disease due to the drug administration. Potential association of anti-TNF- therapy with demyelination is one of neurological adverse reaction, and is an important concern for every day clinical practice of rheumatologist as well as is an interesting problem from pathophysiological point of view.
format	article
author	Eugeniusz Józef Kucharz Anna Kotulska-Kucharz
author_facet	Eugeniusz Józef Kucharz Anna Kotulska-Kucharz
author_sort	Eugeniusz Józef Kucharz
title	Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
title_short	Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
title_full	Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
title_fullStr	Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
title_full_unstemmed	Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
title_sort	tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
publisher	Termedia Publishing House
publishDate	2021
url	https://doaj.org/article/c12f29a7f5784476be57d07b8b576008
work_keys_str_mv	AT eugeniuszjozefkucharz tumornecrosisfactoralphainhibitorsanddemyelinatingdiseasewhatisbehindit AT annakotulskakucharz tumornecrosisfactoralphainhibitorsanddemyelinatingdiseasewhatisbehindit
_version_	1718379554006892544

Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?

Ejemplares similares